Transcriptional control of human p53-regulated genes

Nature Reviews Molecular Cell Biology

Volumn 9, Issue 5, 2008, Pages 402-412

  Riley, Todd ^a,b   Sontag, Eduardo ^b,c   Chen, Patricia ^a   Levine, Arnold ^a,d  

^a INSTITUTE FOR ADVANCED STUDY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; BINDING SITE; CELL AGING; CELL CYCLE ARREST; DNA REPAIR; GENE CONTROL; HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; TRANSCRIPTION REGULATION; CELL TRANSFORMATION; DNA DAMAGE; DNA RESPONSIVE ELEMENT; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PROBABILITY; REGULATORY SEQUENCE; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; BINDING SITES; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; GENE EXPRESSION REGULATION; GENES, P53; HUMANS; MARKOV CHAINS; MOLECULAR SEQUENCE DATA; REGULATORY ELEMENTS, TRANSCRIPTIONAL; REGULATORY SEQUENCES, NUCLEIC ACID; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 42449114966     PISSN: 14710072     EISSN: 14710080     Source Type: Journal    
DOI: 10.1038/nrm2395     Document Type: Article

References (103)

1. Zhao, R. et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev. 14, 981-993 (2000).
2. Feng, Z. et al. The regulation of AMPK β1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 67, 3043-3053 (2007).
3. Funk, W. D., Pak, D. T., Karas, R. H., Wright, W. E. & Shay, J. W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12, 2866-2871 (1992).
4. el Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. & Vogelstein, B. Definition of a consensus binding site for p53. Nature Genet. 1, 45-49 (1992). This paper presents the head-to-head p53-binding motif and the analysis that led to it.
5. Kern, S. E. et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827-830 (1992).
6. Bourdon, J. C. et al. Further characterisation of the p53 responsive element - identification of new candidate genes for trans-activation by p53. Oncogene 14, 85-94 (1997). This paper combines experimental and computational methods to explore new p53 targets. It also discusses the importance of clusters of p53 half-sites in the regulatory expression of target genes.
7. Tan, T. & Chu, G. p53 binds and activates the xeroderma pigmentosum DDB2 gene in humans but not mice. Mol. Cell. Biol. 22, 3247-3254 (2002).
8. WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 55, 2910-2919 (1995).
9. Espinosa, J. M. & Emerson, B. M. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell 8, 57-69 (2001).
10. (waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res. 34, 543-554 (2006).
11. Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307-310 (2000). This review presents the p53 regulatory network, response mechanisms to cell stress and the pathways that suppress cancer occurrence and growth.
12. Levine, A. J., Hu, W. & Feng, Z. The p53 pathway: what questions remain to be explored? Cell Death Differ. 13, 1027-1036 (2006).
13. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997). This review presents the p53 regulatory network and how it functions to reduce the occurrence and how it suppresses the growth of cancer.
14. Manfredi, J. J. p53 and apoptosis: it's not just in the nucleus anymore. Mol. Cell 11, 552-554 (2003).
15. Rollwagen, F. M., Yu, Z. Y., Li, Y. Y. & Pacheco, N. D. IL-6 rescues enterocytes from hemorrhage induced apoptosis in vivo and in vitro by a bcl-2 mediated mechanism. Clin. Immunol. Immunopathol. 89, 205-213 (1998).
16. Yonish-Rouach, E. et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352, 345-347 (1991).
17. Yang, G. et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc. Natl Acad. Sci. USA 103, 16472-16477 (2006).
18. Harris, S. L. & Levine, A. J. The p53 pathway: positive and negative feedback loops. Oncogene 24, 2899-2908 (2005). This paper presents how feedback loops are a common motif in the regulatory pathways involving p53.
19. Feng, Z., Zhang, H., Levine, A. J. & Jin, S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl Acad. Sci. USA 102, 8204-8209 (2005).
20. Yu, X., Harris, S. L. & Levine, A. J. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res. 66, 4795-4801 (2006).
21. Clemens, M. J. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene 23, 3180-3188 (2004).
22. Elela, S. A. & Nazar, R. N. The ribosomal 5.8S RNA as a target site for p53 protein in cell differentiation and oncogenesis. Cancer Lett. 117, 23-28 (1997).
23. Prats, A.-C. & Prats, H. Translational control of gene expression: role of IRESs and consequences for cell transformation and angiogenesis. Prog. Nucleic Acid Res. Mol. Biol. 72, 367-413 (2002).
24. Yin, X., Fontoura, B. M. A., Morimoto, T. & Carroll, R. B. Cytoplasmic complex of p53 and eEF2. J. Cell Physiol. 196, 474-482 (2003).
25. Zhang, Y. et al. Repression of hsp90β gene by p53 in UV irradiation-induced apoptosis of Jurkat cells. J. Biol. Chem. 279, 42545-42551 (2004).
26. Agoff, S. N., Hou, J., Linzer, D. I. & Wu, B. Regulation of the human hsp70 promoter by p53. Science 259, 84-87 (1993).
27. Morris, G. F., Bischoff, J. R. & Mathews, M. B. Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Proc. Natl Acad. Sci. USA 93, 895-899 (1996).
28. Tanaka, H. et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404, 42-49 (2000).
29. Smith, M. L. et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266, 1376-1380 (1994).
30. Feng, Z. et al. p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene 25, 1-7 (2006).
31. Hu, W., Feng, Z., Teresky, A. & Levine, A. J. p53 regulates maternal reproduction through LIF. Nature 450, 721-724 (2007).
32. Farmer, G., Colgan, J., Nakatani, Y., Manley, J. L. & Prives, C. Functional interaction between p53, the TATA-binding protein (TBP), and TBP-associated factors in vivo. Mol. Cell. Biol. 16, 4295-4304 (1996).
33. Thut, C. J., Chen, J. L., Klemm, R. & Tjian, R. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 267, 100-104 (1995).
34. Gu, W., Shi, X. L. & Roeder, R. G. Synergistic activation of transcription by CBP and p53. Nature 387, 819-823 (1997).
35. Gu, W. & Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606 (1997).
36. Lee, K. C., Crowe, A.& Barton, M. C. p53-mediated repression of alpha-fetoprotein gene expression by specific DNA binding. Mol. Cell. Biol. 19, 1279-1288 (1999).
37. Budhram-Mahadeo, V. et al. p53 suppresses the activation of the Bcl-2 promoter by the Brn-3a POU family transcription factor. J. Biol. Chem. 274, 15237-15244 (1999).
38. Ori, A. et al. p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53. EMBO J. 17, 544-553 (1998).
39. Agostino, S. D. et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10, 191-202 (2006).
40. Basile, V., Mantovani, R. & Imbriano, C. DNA damage promotes histone deacetylase 4 nuclear localization and repression of G2/M promoters, via p53 C-terminal lysines. J. Biol. Chem. 281, 2347-2357 (2006).
41. Ceribelli, M., Alcalay, M., Viganò, M. A. & Mantovani, R. Repression of new p53 targets revealed by ChIP on chip experiments. Cell Cycle 5, 1102-1110 (2006). This paper presents experiments that show direct p53-mediated repression through p53-mediated inactivation (squelching) of NF-Y.
42. Chae, H. D., Yun, J. & Shi, D. Y. Transcription repression of a CCAAT-binding transcription factor CBF/HSP70 by p53. Exp. Mol. Med. 37, 488-491 (2005).
43. Imbriano, C. et al. Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol. Cell. Biol. 25, 3737-3751 (2005).
44. Yun, J. et al. p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J. Biol. Chem. 274, 29677-29682 (1999).
45. Jung, M. S. et al. p53 and its homologues, p63 and p73, induce a replicative senescence through inactivation of NF-Y transcription factor. Oncogene 20, 5818-5825 (2001).
46. Matsui, T. et al. Negative regulation of Chk2 expression by p53 is dependent on the CCAAT-binding transcription factor NF-Y. J. Biol. Chem. 279, 25093-25100 (2004).
47. Iotsova, V. & Stehelin, D. Down-regulation of fibronectin gene expression by the p53 tumor suppressor protein. Cell Growth Differ. 7, 629-634 (1996).
48. Subbaramaiah, K. et al. Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem. 274, 10911-10915 (1999).
49. Innocente, S. A. & Lee, J. M. p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription. FEBS Lett. 579, 1001-1007 (2005).
50. Kanaya, T. et al. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin. Cancer Res. 6, 1239-1247 (2000).
51. Ohlsson, C., Kley, N., Werner, H. & LeRoith, D. p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: interaction between p53 and Sp1. Endocrinology 139, 1101-1107 (1998).
52. Kubicka, S. et al. p53 represses CAAT enhancer-binding protein (C/EBP)-dependent transcription of the albumin gene. A molecular mechanism involved in viral liver infection with implications for hepatocarcinogenesis. J. Biol. Chem. 274, 32137-32144 (1999).
53. Sun, Y., Zeng, X.-R., Wenger, L., Firestein, G. S. & Cheung, H. S. P53 down-regulates matrix metalloproteinase-1 by targeting the communications between AP-1 and the basal transcription complex. J. Cell. Biochem. 92, 258-269 (2004).
54. Seto, E. et al. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl Acad. Sci. USA 89, 12028-12032 (1992).
55. Truant, R., Xiao, H., Ingles, C. J. & Greenblatt, J. Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein. J. Biol. Chem. 268, 2284-2287 (1993).
56. Farmer, G., Friedlander, P., Colgan, J., Manley, J. L. & Prives, C. Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein. Nucleic Acids Res. 24, 4281-4288 (1996).
57. Murphy, M. et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 13, 2490-2501 (1999).
58. Harms, K. L. & Chen, X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res. 67, 3145-3152 (2007). This paper shows that HDAC2 represses p53-mediated regulation of genes by reducing the acetylation of Lys residues in the p53 protein.
59. Löhr, K., Möritz, C., Contente, A. & Dobbelstein, M. p21/CDKN1A mediates negative regulation of transcription by p53. J. Biol. Chem. 278, 32507-32516 (2003). This paper presents evidence that many genes are indirectly repressed by p53 through p53-mediated induction of CDKN1A (p21).
60. Hoffman, W. H., Biade, S., Zilfou, J. T., Chen, J. & Murphy, M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 277, 3247-3257 (2002).
61. Johnson, R. A., Ince, T. A. & Scotto, K. W. Transcriptional repression by p53 through direct binding to a novel DNA element. J. Biol. Chem. 276, 27716-27720 (2001).
62. Bist, A., Fielding, C. J. & Fielding, P. E. p53 regulates caveolin gene transcription, cell cholesterol, and growth by a novel mechanism. Biochemistry 39, 1966-1972 (2000).
63. Vousden, K. H. Activation of the p53 tumor suppressor protein. Biochim. Biophys. Acta 1602, 47-59 (2002).
64. Luo, J. et al. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc. Natl Acad. Sci. USA 101, 2259-2264 (2004).
65. Gu, W., Luo, J., Brooks, C. L., Nikolaev, A. Y. & Li, M. Dynamics of the p53 acetylation pathway. Novartis Found. Symp. 259, 197-205 (2004).
66. Chuikov, S. et al. Regulation of p53 activity through lysine methylation. Nature 432, 353-360 (2004).
67. Barlev, N. A. et al. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8, 1243-1254 (2001).
68. McKinney, K. & Prives, C. Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol. Cell. Biol. 22, 6797-6808 (2002).
69. Weinberg, R. L., Veprintsev, D. B., Bycroft, M. & Fersht, A. R. Comparative binding of p53 to its promoter and DNA recognition elements. J. Mol. Biol. 348, 589-596 (2005).
70. Oda, K. et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102, 849-862 (2000).
71. Jaiswal, A. S. & Narayan, S. p53-dependent transcriptional regulation of the APC promoter in colon cancer cells treated with DNA alkylating agents. J. Biol. Chem. 276, 18193-18199 (2001).
72. Minucci, S. & Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Rev. Cancer 6, 38-51 (2006).
73. Halazonetis, T. D., Davis, L. J. & Kandil, A. N. Wild-type p53 adopts a 'mutant'-like conformation when bound to DNA. EMBO J. 12, 1021-1028 (1993).
74. Osada, M. et al. Differential recognition of response elements determines target gene specificity for p53 and p63. Mol. Cell. Biol. 25, 6077-6089 (2005).
75. Cho, Y., Gorina, S., Jeffrey, P. D. & Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265, 346-355 (1994).
76. Inga, A., Storici, F., Darden, T. A. & Resnick, M. A. Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol. Cell. Biol. 22, 8612-8625 (2002).
77. Balagurumoorthy, P., Lindsay, S. M. & Harrington, R. E. Atomic force microscopy reveals kinks in the p53 response element DNA. Biophys. Chem. 101-102, 611-623 (2002).
78. Olson, W. K., Gorin, A. A., Lu, X. J., Hock, L. M. & Zhurkin, V. B. DNA sequence-dependent deformability deduced from protein-DNA crystal complexes. Proc. Natl Acad. Sci. USA 95, 11163-11168 (1998).
79. Wu, M. et al. AMID is a p53-inducible gene downregulated in tumors. Oncogene 23, 6815-6819 (2004).
80. Contente, A., Dittmer, A., Koch, M. C., Roth, J. & Dobbelstein, M. A polymorphic microsatellite that mediates induction of PIG3 by p53. Nature Genet. 30, 315-320 (2002).
81. Thornborrow, E. C., Patel, S., Mastropietro, A. E., Schwartzfarb, E. M. & Manfredi, J. J. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes. Oncogene 21, 990-999 (2002).
82. Koutsodontis, G., Vasilaki, E., Chou, W.-C., Papakosta, P. & Kardassis, D. Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis. Biochem. J. 389, 443-455 (2005). This paper presents experiments that confirm that cofactor-binding sites adjacent to p53-binding sites can be crucial in conferring p53-mediated regulation.
83. Thornborrow, E. C. & Manfredi, J. J. The tumor suppressor protein p53 requires a cofactor to activate transcriptionally the human BAX promoter. J. Biol. Chem. 276, 15598-15608 (2001).
84. Cook, J. L. et al. Distance constraints and stereospecific alignment requirements characteristic of p53 DNA-binding consensus sequence homologies. Oncogene 11, 723-733 (1995).
85. Stenger, J. E. et al. p53 oligomerization and DNA looping are linked with transcriptional activation. EMBO J. 13, 6011-6020 (1994).
86. Bond, G. L. et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119, 591-602 (2004).
87. Burns, T. F., Fei, P., Scata, K. A., Dicker, D. T. & El-Deiry, W. S. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol. Cell. Biol. 23, 5556-5571 (2003).
88. Wang, Y., Schwedes, J. F., Parks, D., Mann, K. & Tegtmeyer, P. Interaction of p53 with its consensus DNA-binding site. Mol. Cell. Biol. 15, 2157-2165 (1995).
89. Tokino, T. et al. p53 tagged sites from human genomic DNA. Hum. Mol. Genet. 3, 1537-1542 (1994).
90. Flores, E. R. et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416, 560-564 (2002).
91. Wei, C.-L. et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 124, 207-219 (2006).
92. Hoh, J. et al. The p53MH algorithm and its application in detecting p53-responsive genes. Proc. Natl Acad. Sci. USA 99, 8467-8472 (2002).
93. Barash, Y., Elidan, G., Friedman, N. & Kaplan, T. in RECOMB '03: Proceedings of the Seventh Annual International Conference on Research in Computational Molecular Biology 28-37 (ACM Press, New York, USA, 2003).
94. Djordjevic, M., Sengupta, A. M. & Shraiman, B. I. A biophysical approach to transcription factor binding site discovery. Genome Res. 13, 2381-2390 (2003).
95. Stormo, G. & Fields, D. Specificity, free energy and information content in protein-DNA interactions. Trends Biochem. Sci. 23, 109-113 (1998).. This paper presents the theory and applicability of position-specific score matrices.
96. Tompa, M. et al. Assessing computational tools for the discovery of transcription factor binding sites. Nature Biotechnol. 23, 137-144 (2005).
97. Wasserman, W. W. & Sandelin, A. Applied bioinformatics for the identification of regulatory elements. Nature Rev. Genet. 5, 276-287 (2004).
98. Yeo, G. & Burge, C. B. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J. Comput. Biol. 11, 377-394 (2004).
99. Krogh, A., Brown, M., Mian, I. S., Sjölander, K. & Haussler, D. Hidden Markov models in computational biology. Applications to protein modeling. J. Mol. Biol. 235, 1501-1531 (1994).
100. Eddy, S. R. Profile hidden Markov models. Bioinformatics 14, 755-763 (1998).
101. Durbin, R., Eddy, S., Krogh, A. & Mitchison, G. Biological Sequence Analysis 1st Edn (Cambridge Univ. Press, 1998). This book provides an excellent introduction to computational methods used to analyse biological sequence data (DNA, RNA and proteins).
102. Stormo, G. D. DNA binding sites: representation and discovery. Bioinformatics 16, 16-23 (2000).
103. Schneider, T. D. & Stephens, R. M. Sequence logos: a new way to display consensus sequences. Nucleic Acids Res. 18, 6097-6100 (1990).